Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 90.14% is 194% above its 3-year average of 30.62%, near the high end of its 3-year range (0.00%–99.62%).
13.24% above its 12-month average of 79.60%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 94.90%.
GROSS MARGIN
90.14%
GROSS MARGIN AVG TTM
79.60%
GROSS MARGIN AVG 3Y
30.62%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.24%
CURRENT VS 3Y AVG
+194.42%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
+123.56%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$118.99M
Gross Margin
90.14%
TTM Avg
79.60%
3Y Avg
30.62%
5Y Avg
0.00%
Market Cap
$117.53M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$121.63M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$116.89M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$122.13M
Gross Margin
-62.76%
TTM Avg
-61.84%
3Y Avg
-230.63%
5Y Avg
-163.28%
Market Cap
$116.59M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$116.35M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$116.34M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$115.36M
Gross Margin
-60.26%
TTM Avg
-75.23%
3Y Avg
-314.56%
5Y Avg
-212.54%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.99M | 90.14% | 79.60% | 30.62% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 67.34% | 64.03% | 72.89% | 33.80% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.89M | 11.17% | 22.02% | 17.41% | 13.61% |
| Cibus, Inc. (CBUS)vs › | $122.13M | -62.76% | -61.84% | -230.63% | -163.28% |
| Genelux Corporation (GNLX)vs › | $116.59M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | 99.91% | -67.10% | -31.47% | -20.98% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.34M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.36M | -60.26% | -75.23% | -314.56% | -212.54% |
| enGene Holdings Inc. (ENGN)vs › | $123.26M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
90.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 94.90% |
| 2026-03-31 | 37.56% |
| 2025-12-31 | 66.94% |
| 2025-09-30 | 99.00% |
| 2025-06-30 | 99.62% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
